ArticleStem cell research & therapy2026
Optimization of polyethylene glycol-based isolation of exosomes from mesenchymal stem cells for regenerative medicine applications.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMesenchymal stem cells (MSCs) and their derived exosomes have gained significant attention in regenerative medicine due to their unique therapeutic properties, including immunomodulatory and regenerative capabilities. However, the development of a simple, scalable, and reproducible method for isolating exosomes from MSC-conditioned media remains a challenge.
methodsWe optimized a polyethylene glycol (PEG)-based precipitation method for exosome isolation by initially evaluating three different PEG molecular weights (1140, 3350, and 8000 Da). Protein quantification and nanoparticle tracking analysis (NTA) were performed for all three PEG types to assess yield and particle size. Based on these results, PEG 3350 and PEG 8000 were selected for further characterization by scanning electron microscopy (SEM), size exclusion chromatography (SEC), and Western blotting. Subsequently, proteomic and metabolomic analyses were conducted using exosomes isolated with PEG 3350. For functional assays, HeLa cells were exposed to increasing concentrations of MSC-derived exosomes under either 1% or 10% fetal bovine serum (FBS). Cell viability was evaluated at 24 h and 48 h using the the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay.
resultsOur results demonstrated that PEG 3350 provided the highest yield and purity of MSC-derived exosomes. The isolated exosomes exhibited an average size below 200 nm, as confirmed by SEM and NTA. Western blotting validated the presence of exosome-specific markers CD63, CD9, and LGALS3BP, while liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis identified 357 proteins and 1,085 metabolites, confirming the molecular integrity of the exosomes. Additionally, SEC analysis revealed that repeated PEG-based enrichment cycles effectively improved exosome purity by removing non-vesicular contaminants. Functionally, exosomes isolated with PEG 3350 exhibited no cytotoxicity in HeLa cells and, at higher concentrations, promoted a condition-dependent increase in cell viability.
conclusionsThis study presents an optimized PEG 3350-based method for exosome isolation, providing a scalable and reproducible approach for obtaining high-purity MSC-derived exosomes. These findings have significant implications for the development of exosome-based therapeutics in regenerative medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.